Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/18/2017 07/19/2017 07/20/2017 07/21/2017 07/24/2017 Date
65.89(c) 65.91(c) 65.73(c) 65.46(c) 63.6 Last
161 707 108 393 78 578 109 921 223 905 Volume
-1.61% +0.03% -0.27% -0.41% -2.84% Change
More quotes
Financials (€)
Sales 2017 52,9 M
EBIT 2017 -52,5 M
Net income 2017 -65,2 M
Finance 2017 228 M
Yield 2017 -
Sales 2018 43,5 M
EBIT 2018 -58,0 M
Net income 2018 -68,5 M
Finance 2018 206 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 32,0x
EV / Sales2018 39,4x
Capitalization 1 920 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery and Proprietary Development.The Partnered Discovery segment involves technologies for the generation of human antibody... 
Sector
Biotechnology & Medical Research
Calendar
08/03 | 07:00amEarnings Release
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
07/21 MORPHOSYS AG : Adhoc: MorphoSys Announces that Its Partner, Bayer, Reports on Ph..
07/21 MORPHOSYS AG : MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 S..
07/21 DGAP-NEWS : MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study ..
07/21 ADHOC : MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of I..
07/21 DGAP-ADHOC : Adhoc: MorphoSys Announces That Its Partner Bayer Reports On Phase ..
07/14 MORPHOSYS : Announces That Its Licensee Janssen Has Received US FDA Approval for..
07/13 MORPHOSYS AG : MorphoSys Announces that Its Licensee, Janssen, Has Received US F..
07/13 MEDIA RELEASE : MorphoSys Announces That Its Licensee Janssen Has Received US FD..
07/13 ADHOC : MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approv..
07/13 DGAP-NEWS : Media Release: MorphoSys Announces That Its Licensee Janssen Has Rec..
More news
Sector news : Biotechnology & Medical Research - NEC
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01:13pMorphoSys AG given €77.00 PT by Independent Research GmbH. buy rating.  
10:08aMorphoSys AG given €76.00 PT by Commerzbank Ag. buy rating.  
09:18aMorphoSys AG given €55.00 PT by Goldman Sachs Group, Inc. (The). neutral rati.. 
07/21Morphosys: Monotherapy w/ partner Bayer's anetumab ravtansine for recurrent m..
3
07/17MorphoSys AG given €77.00 PT by Independent Research GmbH. buy rating.  
More tweets
Qtime:13
News from SeekingAlpha
06/23 Morphosys AG (MPSYF) Presents At DbAccess Berlin Conference - Slideshow
05/06 Morphosys' (MPSYF) CEO Simon Moroney on Q1 2017 Results - Earnings Call Trans..
05/06 MorphoSys AG 2017 Q1 - Results - Earnings Call Slides
05/03 MorphoSys AG reports Q1 results
03/09 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2016 Results - Earnings Call Trans..
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 70,1 €
Spread / Average Target 7,2%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Günter Wellnhofer Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG34.28%2 238
INCYTE CORPORATION33.86%27 485
QUINTILES IMS HOLDINGS INC19.86%19 672
LONZA GROUP31.59%16 914
CELLTRION, INC.--.--%12 564
ALKERMES PLC3.87%8 844